A 60-year-old man with unstable angina is treated with an intravenously administered glycoprotein IIb-IIIa inhibitor. The mechanism of action of this agent is the ability to: (A) Dilate coronary aeries., (B) Inhibit atherogenesis., (C) Inhibit platelet adhesion., (D) Inhibit platelet aggregation.
Answer is D. Glycoprotein IIb-IIIa inhibitors Prevent the action of the platelet surface receptor glycoprotein complex, which is required for formation of fibrinogen bridges between adjacent platelets Thus inhibiting platelet aggregation. Ex- TICLOPIDINE,CLOPIDOGREL,PRASUGREL